Oral Leukoplakia Clinical Trial
Official title:
Phase I Study of Photodynamic Therapy Using Pulsed Dye Laser and Oral Aminolevulinic Acid in Patients With Oral Leukoplakia
This phase I trial studies the side effects and best dose of photodynamic therapy using aminolevulinic acid in treating patients with oral leukoplakia. Photodynamic therapy uses a drug, such as aminolevulinic acid, that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using aminolevulinic acid may be effective against oral leukoplakia.
PRIMARY OBJECTIVES:
I. To determine the toxicity and feasibility of photodynamic therapy using pulsed laser
therapy and oral aminolevulinic acid in treating patients with oral leukoplakia.
II. To define the dose-limiting toxicity and maximum tolerated dose of photodynamic therapy
using pulsed laser therapy and oral aminolevulinic acid in these patients.
SECONDARY OBJECTIVES:
I. To assess the efficacy of photodynamic therapy using pulsed dye laser and oral
aminolevulinic acid by examining clinical response at 1 and 3 months.
II. To determine quantitative histologic response at 3 months. III. To explore the
association of response with specific molecular and biologic markers (i.e., DNA ploidy,
proliferation using Ki-67, apoptosis using TUNEL, cyclin D1, and p53).
OUTLINE: This is a dose-escalation study of long pulsed dye laser light.
Patients receive aminolevulinic acid* orally (PO) 3-4 hours before undergoing photodynamic
therapy using pulsed dye laser on day 1.
(Note: *Patients in cohort 1 and a latter cohort [to be determined during the course of the
study] do not receive aminolevulinic acid before photodynamic therapy.)
Patients undergo biopsies of target lesions and clinically uninvolved mucosa 4-8 weeks
before beginning therapy and then at 3 months for biomarker studies (DNA ploidy, p53, Ki-67,
cyclin D1, and TUNEL assay). Blood is collected on days 1, 2, 14, 28, and 84 for toxicity
assessment.
After completion of study treatment, patients are followed for up to 84 days.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05505539 -
Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia
|
Phase 1 | |
Terminated |
NCT00176566 -
A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia
|
Phase 2 | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
Completed |
NCT04712929 -
Candida Associated Cytokines in Oral Leukoplakia
|
||
Completed |
NCT03031899 -
Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy
|
||
Recruiting |
NCT06321003 -
SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
|
||
Not yet recruiting |
NCT04732741 -
Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions
|
||
Completed |
NCT00369174 -
Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia
|
Phase 2 | |
Completed |
NCT00099021 -
Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
|
Phase 2 | |
Not yet recruiting |
NCT05727761 -
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
|
Phase 2 | |
Active, not recruiting |
NCT02581137 -
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
|
Phase 2 | |
Recruiting |
NCT05942794 -
Identification of Oral Lesions Through an Autofluorescence System
|
N/A | |
Completed |
NCT00330382 -
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
|
Phase 2 | |
Recruiting |
NCT05237960 -
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
|
Phase 2 | |
Not yet recruiting |
NCT06256809 -
Analyzing Handprint Patterns to Predict Oral Cancer Risks: A Comparative Study
|
||
Completed |
NCT00951379 -
Pioglitazone for Oral Premalignant Lesions
|
Phase 2 | |
Recruiting |
NCT04251845 -
Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia
|
N/A | |
Terminated |
NCT04079491 -
Intra and Extra Oral Inspection of Oral Mucosa
|
||
Recruiting |
NCT00767442 -
Least Invasive Nonlinear Light Microscopy
|
N/A |